Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.

被引：0
|
作者：
Gray, Jhanelle Elaine
Owonikoko, Taofeek Kunle
Kato, Terufumi
Zorrilla, Andres Felipe Cardona
Wagman, Joanne
Chen, Xinqun
Zhao, Bin
Schulz, Christian
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Kanagawa Canc Ctr, Div Thorac Oncol, Yokohama, Kanagawa, Japan
[4] Inst Oncol, Clin Country, Clin & Translat Oncol Grp, Bogota, Colombia
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] Klinikum Univ Regensburg, Bereich Pneumol, Klin & Poliklin Innere Med 2, Regensburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9632
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
    Gray, Jhanelle E.
    Schenker, Michael
    Sendur, Mehmet Ali Nahit
    Leonova, Viktoriya
    Kowalski, Dariusz
    Kato, Terufumi
    Orlova, Rashida
    Yang, James Chih-Hsin
    Langleben, Adrian
    Pilz, Arnold
    Ungureanu, Andrei
    Mak, Milena Perez
    De Angelis, Flavia
    Aggarwal, Himani
    Zimmer, Zachary
    Zhao, Bin
    Shamoun, Mark
    Kim, Tae Min
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (02) : 219 - 232
  • [2] Pembrolizumab Plus Maintenance Olaparib as FirstLine Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study
    Gray, J.
    Schenker, M.
    Sendur, M. A. N.
    Kim, S. -W.
    Leonova, V.
    Kowalski, D.
    Kato, T.
    Orlova, R.
    Yang, J. C. -H.
    Langleben, A.
    Breyer, M. -K.
    Ungureanu, A.
    Mak, M. Perez
    De Angelis, F.
    Zimmer, Z.
    Zhao, B.
    Shamoun, M.
    Kim, T. M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S98 - S98
  • [3] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    ANNALS OF ONCOLOGY, 2015, 26
  • [5] First-line pembrolizumab plus platinum-pemetrexed in metastatic non-small cell lung cancer: Clinical experience in a Spanish tertiary hospital
    Lombardero, Lara
    De Elejoste, Ibone
    Casas, Raquel
    Azcuna, Josune
    Ortega, Berezi
    Mohamed Lamin, Failah
    Jimenez Labaig, Pablo
    Rubio, Itziar
    Munoz Llarena, Alberto
    Azkona, Eider
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (01) : 23 - 28
  • [7] Randomized phase II study of pemetrexed plus carboplatin followed by pemetrexed versus paclitaxel plus carboplatin followed by pemetrexed in advanced nonsquamous, non-small cell lung cancer (LOGIK 0904)
    Takayama, Koichi
    Inoue, Koji
    Takeshita, Masafumi
    Tashiro, Naoki
    Harada, Taishi
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Ichinose, Yukito
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer
    Goldschmidt, Jerome H.
    Annavarapu, Srinivas
    Venkatasetty, Divea
    Wang, Yunfei
    Santorelli, Melissa L.
    Burke, Thomas
    Pennell, Nathan A.
    IMMUNOTHERAPY, 2024, 16 (07) : 453 - 464
  • [9] PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Zinner, Ralph G.
    Obasaju, Coleman K.
    Spigel, David R.
    Weaver, Robert W.
    Beck, J. Thaddeus
    Waterhouse, David M.
    Modiano, Manuel R.
    Hrinczenko, Borys
    Nikolinakos, Petros G.
    Liu, Jingyi
    Koustenis, Andrew G.
    Winfree, Katherine B.
    Melemed, Symantha A.
    Guba, Susan C.
    Ortuzar, Waldo I.
    Desaiah, Durisala
    Treat, Joseph A.
    Govindan, Ramaswamy
    Ross, Helen J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 134 - 142
  • [10] THE RISK OF TREATMENT WITH PEMETREXED PLUS PLATINUM FOLLOWED BY MAINTENANCE WITH PEMETREXED FOR PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER CONCURRENT WITH INTERSTITIAL LUNG DISEASE
    Fujita, Tetsuo
    Kuroki, Tsuguko
    Shiraishi, Yuka
    Amano, Hiroyuki
    Nakamura, Makoto
    Hirano, Satoshi
    Tabeta, Hiroshi
    Nakamura, Sukeyuki
    CHEST, 2019, 156 (04) : 1716A - 1716A
12345